Key Considerations of Balancing Investor Relations in Biotech

PE: What are some key considerations when balancing investor relations with the long-term clinical and scientific priorities of a biotech company?
Smith: So first and foremost is you should try to align yourself with anchor investors who truly, Truly understand the industry, truly, truly understand your science and your clinical and regulatory opportunity, and truly have a long term view of the potential for value creation. If you can do those things, they should expect that not every. Single success or failure will be rewarded or penalized by Wall Street in the same way that your capital today may and may require more capital in the future, and that you're going to have the potential to grow, but they're going to be the path is rarely linear. There's timing involved. There's sometimes and frequently luck involved. Capital Markets have to be supportive at the right time. So a lot of stars have to align for a biotechnology company to be successful. And you want to be you want to have shareholders who appreciate that and who are patient enough to give you the right amount of running room when it's appropriate.